{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:14:52Z","timestamp":1792844092532,"version":"4.5.0"},"reference-count":121,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"StemLine","award":["X"],"award-info":[{"award-number":["X"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>CD123, the \u03b1 chain of the interleukin 3 receptor, is a cytokine receptor that is overexpressed in multiple hematolymphoid neoplasms, including acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, acute lymphoblastic leukemia, hairy cell leukemia, and systemic mastocytosis. Importantly, CD123 expression is upregulated in leukemic stem cells relative to non-neoplastic hematopoietic stem cells, which makes it a useful diagnostic and therapeutic biomarker in hematologic malignancies. Varying levels of evidence have shown that CD123-targeted therapy represents a promising therapeutic approach in several cancers. Tagraxofusp, an anti-CD123 antibody conjugated to a diphtheria toxin, has been approved for use in patients with blastic plasmacytoid dendritic cell neoplasm. Multiple clinical trials are investigating the use of various CD123-targeting agents, including chimeric antigen receptor-modified T cells (expressing CD123, monoclonal antibodies, combined CD3-CD123 dual-affinity retargeting antibody therapy, recombinant fusion proteins, and CD123-engager T cells. In this review, we provide an overview of laboratory techniques used to evaluate and monitor CD123 expression, describe the strengths and limitations of detecting this biomarker in guiding therapy decisions, and provide an overview of the pharmacologic principles and strategies used in CD123-targeted therapies.<\/jats:p>","DOI":"10.3390\/cancers12113087","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T08:59:28Z","timestamp":1603443568000},"page":"3087","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6480-3182","authenticated-orcid":false,"given":"Hanadi","family":"El Achi","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, The University of Texas at Houston, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Dupont","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy of Paris, Paris Descartes University, 75270 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"ref_1","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Carnicer","year":"2001","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/stem.170265","article-title":"Correlation between IL-3 receptor expression and growth potential of human CD34+ hematopoietic cells from different tissues","volume":"17","author":"Huang","year":"1999","journal-title":"Stem Cells"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11872","DOI":"10.1073\/pnas.172384399","article-title":"Prospective isolation of human clonogenic common myeloid progenitors","volume":"99","author":"Manz","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2019). CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers, 11.","DOI":"10.3390\/cancers11091358"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/imr.12774","article-title":"Updates on CAR T-cell therapy in B-cell malignancies","volume":"290","author":"Jacoby","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-065X.2012.01164.x","article-title":"The GM-CSF\/IL-3\/IL-5 cytokine receptor family: From ligand recognition to initiation of signaling","volume":"250","author":"Broughton","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/stem.160301","article-title":"Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors","volume":"16","author":"Guthridge","year":"1998","journal-title":"Stem Cells"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lfs.2014.10.013","article-title":"CD123 and its potential clinical application in leukemias","volume":"122","author":"Liu","year":"2015","journal-title":"Life Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12185-019-02616-y","article-title":"Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia","volume":"109","author":"Arai","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41467-017-02633-7","article-title":"A dual role for the N-terminal domain of the IL-3 receptor in cell signalling","volume":"9","author":"Broughton","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood.V89.3.842","article-title":"Roles of the N and C terminal domains of the interleukin-3 receptor alpha chain in receptor function","volume":"89","author":"Barry","year":"1997","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0268-960X(91)90036-C","article-title":"The cytokine receptor superfamily","volume":"5","author":"Kaczmarski","year":"1991","journal-title":"Blood Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.celrep.2014.06.038","article-title":"Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibody","volume":"8","author":"Broughton","year":"2014","journal-title":"Cell Rep."},{"key":"ref_17","first-page":"1146","article-title":"Gene for the alpha-subunit of the human interleukin-3 receptor (IL3RA) localized to the X-Y pseudoautosomal region","volume":"53","author":"Milatovich","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1006\/bbrc.1995.1346","article-title":"Structure of the gene encoding the alpha subunit of the human interleukin 3 receptor","volume":"208","author":"Kosugi","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cytogfr.2013.03.002","article-title":"Signalling by the \u03b2c family of cytokines","volume":"24","author":"Hercus","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/0008-5472.CAN-03-3693","article-title":"CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD\/SCID mice","volume":"64","author":"Tavor","year":"2004","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/bloodadvances.2016002931","article-title":"High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression","volume":"1","author":"Wittwer","year":"2017","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wang, W., Khoury, J.D., Miranda, R.N., Jorgensen, J.L., Xu, J., Loghavi, S., Li, S., Pemmaraju, N., Nguyen, T., and Medeiros, L.J. (2020). Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica.","DOI":"10.3324\/haematol.2020.247569"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-17-1597","article-title":"Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial","volume":"24","author":"Khoury","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11899-019-00533-9","article-title":"Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection","volume":"14","author":"Sukswai","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/PAS.0000000000001316","article-title":"Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"43","author":"Sukswai","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11899-018-0489-z","article-title":"Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"13","author":"Khoury","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sukswai, N., Jung, H.R., Amr, S.S., Ng, S.B., Sheikh, S.S., Lyapichev, K., El Hussein, S., Loghavi, S., Agbay, R., and Miranda, R.N. (2019). Immunopathology of Kikuchi-Fujimoto disease: A reappraisal using novel immunohistochemistry markers. Histopathology.","DOI":"10.1111\/his.14050"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23567","article-title":"TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow","volume":"88","author":"Alayed","year":"2013","journal-title":"Am. J. Hematol"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11899-018-0475-5","article-title":"Recent Updates on Chronic Myelomonocytic Leukemia","volume":"13","author":"Loghavi","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.clml.2019.03.012","article-title":"Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia","volume":"19","author":"Liu","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2141.2008.07491.x","article-title":"Interleukin (IL)-3\/granulocyte macrophage-colony stimulating factor\/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor","volume":"144","author":"Riccioni","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/PAI.0b013e318261a342","article-title":"CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations","volume":"21","author":"Pillai","year":"2013","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_35","first-page":"3929","article-title":"Epigenetic Drugs Selectively Target a Population of AML Cells Which Are Positive for CD123 Cell Surface Marker and Are Chemoresistant","volume":"130","author":"Yan","year":"2017","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nakase, K., Kita, K., Kyo, T., Ueda, T., Tanaka, I., and Katayama, N. (2015). Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor \u03b1-Chain (CD25) Expression Predicts a Poor Prognosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128998"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Li, J., Ran, Q., Xu, B., Luo, X., Song, S., Xu, D., and Zhang, X. (2020). Role of CD25 expression on prognosis of acute myeloid leukemia: A literature review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236124"},{"key":"ref_38","first-page":"2034","article-title":"Expression of CD123 and CD114 on the bone marrow cells of patients with myelodysplastic syndrome","volume":"123","author":"Yue","year":"2010","journal-title":"Chin. Med. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12185-014-1590-2","article-title":"Increased CD34+CD38 -CD123 + cells in myelodysplastic syndrome displaying malignant features similar to those in AML","volume":"100","author":"Li","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1038\/s41467-018-05984-x","article-title":"Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes","volume":"9","author":"Stevens","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2015.348","article-title":"CD123 immunostaining patterns in systemic mastocytosis: Differential expression in disease subgroups and potential prognostic value","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1189\/jlb.5RU0614-296R","article-title":"The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis","volume":"97","author":"Teodosio","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood.V120.21.1746.1746","article-title":"CD30\/CD123 Expression in Systemic Mastocytosis Does Not Correlate with Aggressive Disease","volume":"120","author":"Moonim","year":"2012","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Muselli, F., Peyron, J.-F., and Mary, D. (2019). Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225616"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/bjh.12978","article-title":"SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia","volume":"166","author":"Frolova","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2013-07-517847","article-title":"The IL-2\/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells","volume":"123","author":"Kobayashi","year":"2014","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lyapichev, K.A., Sukswai, N., Angelova, E., Kersh, M.J., Pierce, S., Konopleva, M., Jain, N., Jabbour, E.J., Jorgensen, J.L., and Wang, S.A. (2020). CD123 Expression in Philadelphia-chromosome-Like B Acute Lymphoblastic Leukemia\/Lymphoma. Clin. Lymphoma Myeloma Leuk.","DOI":"10.1016\/j.clml.2020.09.014"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1182\/blood.V126.23.5402.5402","article-title":"Use of CD 123 Expression on Blasts from AML, ALL and RAEB As Minimal Residual Disease Marker","volume":"126","author":"Mekkaoui","year":"2015","journal-title":"Blood"},{"key":"ref_52","first-page":"247","article-title":"Assessment of Expression and Prognostic Significance of Interleukin 3 Receptor Alpha Subunit (CD123) in Childhood Acute Lymphoblastic Leukemia","volume":"2","author":"Shaker","year":"2016","journal-title":"Int. J. Med. Res. Prof."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: A high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15960","article-title":"Early T precursor acute lymphoblastic leukaemia\/lymphoma shows differential immunophenotypic characteristics including frequent CD 33 expression and in vitro response to targeted CD 33 therapy","volume":"184","author":"Khogeer","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_55","first-page":"303","article-title":"The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes","volume":"89","author":"Matutes","year":"2004","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1309\/AJCPKUM9J4IXCWEU","article-title":"Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: Usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders","volume":"136","author":"Venkataraman","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0002-9440(10)64878-X","article-title":"Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells","volume":"160","author":"Aldinucci","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1182\/blood.V118.21.3737.3737","article-title":"Hodgkin\u2019s Lymphoma Cell Lines Have up-Regulated IL-3 Receptor \u03b1 (IL-3R\u03b1) Expression and Are Sensitive to SL-401, An IL-3R\u03b1 Targeted Drug","volume":"118","author":"Diefenbach","year":"2011","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.leu.2401743","article-title":"Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias","volume":"14","author":"Frankel","year":"2000","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10428190701799035","article-title":"Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia","volume":"49","author":"Frankel","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/1078-0432.CCR-05-2070","article-title":"Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors","volume":"12","author":"Hogge","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","article-title":"A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia","volume":"56","author":"He","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2019-131217","article-title":"Results from a Phase 1\/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed\/Refractory Myelofibrosis","volume":"134","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","article-title":"Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia","volume":"33","author":"Lucas","year":"2019","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1200\/JCO.2019.37.15_suppl.7059","article-title":"Results from ongoing phase 1\/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed\/refractory chronic myelomonocytic leukemia (CMML)","volume":"37","author":"Patnaik","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1038\/leu.2017.135","article-title":"A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells","volume":"31","author":"Ray","year":"2017","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8599","DOI":"10.1200\/jco.2014.32.15_suppl.8599","article-title":"Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease","volume":"32","author":"Chauhan","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/j.clml.2017.07.022","article-title":"Expression of CD 123 in Acute Lymphoblastic Leukemia and its Prognostic Impact","volume":"17","author":"Eldin","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1182\/blood.V128.22.5696.5696","article-title":"Results from Ongoing Phase 1\/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","volume":"128","author":"Htut","year":"2016","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3324\/haematol.2014.111740","article-title":"In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent","volume":"100","author":"Roggy","year":"2015","journal-title":"Haematologica"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_74","unstructured":"Food and Drug Administration (2020, March 30). FDA Approves Tagraxofusp-Erzs for Blastic Plasmacytoid Dendritic Cell Neoplasm, Available online: https:\/\/www.fda.gov\/drugs\/fda-approves-tagraxofusp-erzs-blastic-plasmacytoid-dendritic-cell-neoplasm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/17512433.2019.1662297","article-title":"Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm","volume":"12","author":"Economides","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.stem.2009.04.018","article-title":"Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells","volume":"5","author":"Jin","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/leu.2014.128","article-title":"Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC","volume":"28","author":"Busfield","year":"2014","journal-title":"Leukemia"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3324\/haematol.2014.113092","article-title":"Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice","volume":"100","author":"Lee","year":"2015","journal-title":"Haematologica"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/blood.V124.21.120.120","article-title":"First-in Man, Phase 1 Study of CSL362 (Anti-IL3R\u03b1\/Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse","volume":"124","author":"Smith","year":"2014","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1038\/bcj.2017.52","article-title":"CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission","volume":"7","author":"Xie","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V126.23.1349.1349","article-title":"First Preclinical Report of the Efficacy and PD Results of KHK2823, a Non-Fucosylated Fully Human Monoclonal Antibody Against IL-3R\u03b1","volume":"126","author":"Akiyama","year":"2015","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2018-99-113112","article-title":"Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents\u2014Final Results of the Samba Trial","volume":"132","author":"Kubasch","year":"2018","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-018-0168-2","article-title":"Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6\/PLD-1","volume":"9","author":"Ernst","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1182\/blood-2012-12-475194","article-title":"Monoclonal antibody targeting of IL-3 receptor \u03b1 with CSL362 effectively depletes CML progenitor and stem cells","volume":"123","author":"Nievergall","year":"2014","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3324\/haematol.2017.187385","article-title":"CD16(+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice","volume":"103","author":"Williams","year":"2018","journal-title":"Haematologica"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"289ra82","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2019-128485","article-title":"Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart\u00ae Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients","volume":"134","author":"Godwin","year":"2019","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2141.2009.08033.x","article-title":"Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells","volume":"148","author":"Stein","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2018-99-119786","article-title":"Complete Responses in Relapsed\/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-015-0109-5","article-title":"AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/mt.2014.156","article-title":"Engager T cells: A new class of antigen-specific T cells that redirect bystander T cells","volume":"23","author":"Iwahori","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1016\/j.bbmt.2017.12.214","article-title":"Improving CD123-Targeted T-Cell Therapy for Acute Myeloid Leukemia","volume":"24","author":"Doherty","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tips.2011.09.004","article-title":"Interleukin-15 biology and its therapeutic implications in cancer","volume":"33","author":"Steel","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2018-99-116811","article-title":"IL15 Expressing CD123-Targeted Engager T-Cell Therapy for Adult Acute Myeloid Leukemia","volume":"132","author":"Mu","year":"2018","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","article-title":"Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"ref_100","unstructured":"Astor, L. (2020, May 01). FDA Grants Orphan Drug Designation to Cd123-Targeted Car T-Cell Therapy for Aml. Available online: https:\/\/www.targetedonc.com\/view\/fda-grants-orphan-drug-designation-to-cd123targeted-car-tcell-therapy."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","article-title":"Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML","volume":"9","author":"Yao","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/protein\/gzs040","article-title":"Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells","volume":"25","author":"Kuo","year":"2012","journal-title":"Protein Eng. Des. Sel."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform","volume":"127","author":"Rettig","year":"2016","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: A mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1182\/blood-2019-125966","article-title":"A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART\u00ae Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2141.2010.08300.x","article-title":"A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting","volume":"150","author":"Stein","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e1472195","DOI":"10.1080\/2162402X.2018.1472195","article-title":"Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells","volume":"7","author":"Braciak","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/S0301-472X(99)00118-6","article-title":"Use of combinatorial mutagenesis to select for multiply substituted human interleukin-3 variants with improved pharmacologic properties","volume":"27","author":"Klein","year":"1999","journal-title":"Exp. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"ref_111","unstructured":"Daver, N. (2020, April 09). Ash 2019: Findings from Phase i Study of Imgn632 Shows Potential in Aml and Bpdcn. Available online: https:\/\/www.adcreview.com\/news\/ash-2019-findings-from-phase-i-study-of-imgn632-shows-potential-in-aml-and-bpdcn\/."},{"key":"ref_112","unstructured":"FDA (2020, April 09). FDA Approves Tisagenlecleucel for B-Cell ALL and Tocilizumab for Cytokine Release Syndrome, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome."},{"key":"ref_113","unstructured":"National Cancer Institute (2020, May 01). FDA Approves Second CAR T-Cell Therapy for Lymphoma, Available online: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/tisagenlecleucel-fda-lymphoma."},{"key":"ref_114","unstructured":"FDA (2020, April 09). FDA Approves Axicabtagene Ciloleucel for Large B-Cell Lymphoma, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/10428194.2019.1605071","article-title":"Recent advances in the treatment of acute lymphoblastic leukemia","volume":"60","author":"Rafei","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_116","unstructured":"Cellectis (2020, May 01). Cellectis Reports Clinical Hold of Ucart123 Studies. Available online: https:\/\/www.cellectis.com\/en\/press\/cellectis-reports-clinical-hold-of-ucart123-studies."},{"key":"ref_117","unstructured":"Immuno-Oncology (2020, May 01). FDA Lifts Clinical Hold on Cellectis\u2019 UCART123 Phase 1 Trials in AML, BPDCN. Available online: https:\/\/immuno-oncologynews.com\/2017\/11\/09\/cellectis-receives-fda-approval-resume-ucart123-aml-bpdcn-trials\/."},{"key":"ref_118","first-page":"1359","article-title":"Treating Relapsed\/Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Budde, L.E., Son, J., Del Real, M., Kim, Y., Toribio, C., Wood, B., Wagner, J., Marcucci, E., Stein, A., and Marcucci, G. (2020). Abstract PR14: CD123CAR displays clinical activity in relapsed\/refractory (r\/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study. Cancer Immunol. Res., 8.","DOI":"10.1158\/2326-6074.TUMIMM18-PR14"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2019.05.002","article-title":"CD123 CAR T cells for the treatment of myelodysplastic syndrome","volume":"74","author":"Stevens","year":"2019","journal-title":"Exp. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:26:41Z","timestamp":1760178401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":121,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["cancers12113087"],"URL":"https:\/\/doi.org\/10.3390\/cancers12113087","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]}}}